CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
51.58
-0.59 (-1.13%)
At close: Dec 2, 2025, 4:00 PM EST
51.61
+0.03 (0.06%)
After-hours: Dec 2, 2025, 7:56 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 18 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $71.5, which forecasts a 38.62% increase in the stock price over the next year. The lowest target is $32 and the highest is $120.
Price Target: $71.5 (+38.62%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 7 | 6 | 6 | 6 | 6 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 → $74 | Strong Buy | Maintains | $82 → $74 | +43.47% | Nov 26, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $87 → $77 | Strong Buy | Maintains | $87 → $77 | +49.28% | Nov 12, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $42 → $50 | Hold | Maintains | $42 → $50 | -3.06% | Nov 11, 2025 |
| Baird | Baird | Hold Maintains $52 → $44 | Hold | Maintains | $52 → $44 | -14.70% | Nov 11, 2025 |
| Needham | Needham | Strong Buy Maintains $81 → $80 | Strong Buy | Maintains | $81 → $80 | +55.10% | Nov 10, 2025 |
Financial Forecast
Revenue This Year
29.65M
from 37.31M
Decreased by -20.53%
Revenue Next Year
145.87M
from 29.65M
Increased by 391.94%
EPS This Year
-6.32
from -4.34
EPS Next Year
-4.33
from -6.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 134.7M | 1.5B | |||
| Avg | 29.7M | 145.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 260.9% | 5,049.7% | |||
| Avg | -20.5% | 391.9% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.37 | 2.89 | |||
| Avg | -6.32 | -4.33 | |||
| Low | -7.18 | -6.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.